Abstract
We present a case of Pembrolizumab-associated ophthalmoplegia in a patient with HNSCC who previously developed an immune checkpoint inhibitor associated hepatitis. Immune checkpoint inhibitor– associated ocular toxicities are rare, occurring in approximately <1% to 1.1% of treated patients.1,2 This case highlights the diagnostic challenges of neuroophthalmic immune-related adverse events and the importance of prompt evaluation and immunosuppressive therapy.
Recommended Citation
Shah, MD, Mohammed; Nair, MD, Smriti; Sulkowski, MD, Sarah; and Imran, BS, Maheen
(2026)
"Delayed Immune-Related Ophthalmoplegia After Pembrolizumab Therapy: A Case Report,"
The Medicine Forum: Vol. 27, Article 27.
Available at:
https://jdc.jefferson.edu/tmf/vol27/iss1/27
